Clinical trial
Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer
NCT00004893
Study timeline
Study start (unknown)1999-12-01Date precision: month
Registry last updated2016-07-19
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
recombinant interleukin-12BIOLOGICAL
Sponsors & collaborators
Alliance for Clinical Trials in Oncologylead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
New YorkNew York, United States3ChicagoIllinois, United States3SyracuseNew York, United States3San FranciscoCalifornia, United States2DurhamNorth Carolina, United States2Washington D.C.District of Columbia, United States2MinneapolisMinnesota, United States2RichmondVirginia, United States2Winston-SalemNorth Carolina, United States2MemphisTennessee, United States2BuffaloNew York, United States2ColumbiaMissouri, United States2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00004893 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.